Voya Investment Management LLC Buys 16,786 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Voya Investment Management LLC increased its stake in Supernus Pharmaceuticals by 39.2%, acquiring an additional 16,786 shares for a total of 59,594 shares worth approximately $1.95 million.
• Insider transactions saw Frank Mottola selling 14,000 shares at $44.51 and Frederick M. Hudson selling 7,457 shares at $42.26, indicating a significant reduction in their holdings.
• Several analysts have upgraded their ratings on Supernus Pharmaceuticals, with Cantor Fitzgerald raising its price target to $46.00 and Zacks Research upgrading the stock to a "strong-buy" rating.

Voya Investment Management LLC increased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 39.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 59,594 shares of the specialty pharmaceutical company's stock after purchasing an additional 16,786 shares during the period. Voya Investment Management LLC owned approximately 0.11% of Supernus Pharmaceuticals worth $1,952,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Vident Advisory LLC increased its position in Supernus Pharmaceuticals by 2.2% in the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock worth $520,000 after purchasing an additional 309 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Supernus Pharmaceuticals by 2.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company's stock worth $480,000 after purchasing an additional 350 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Supernus Pharmaceuticals by 4.7% in the first quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company's stock worth $527,000 after purchasing an additional 726 shares during the last quarter. Quantinno Capital Management LP increased its position in Supernus Pharmaceuticals by 11.5% in the fourth quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock worth $304,000 after purchasing an additional 864 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its position in Supernus Pharmaceuticals by 0.7% during the fourth quarter. Nuveen Asset Management LLC now owns 134,127 shares of the specialty pharmaceutical company's stock valued at $4,850,000 after acquiring an additional 903 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 14,000 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $44.51, for a total value of $623,140.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares of the company's stock, valued at $689,726.96. This trade represents a 47.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director directly owned 46,307 shares of the company's stock, valued at $1,956,933.82. The trade was a 13.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 246,506 shares of company stock worth $10,696,144 over the last ninety days. 8.80% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Stock Down 0.2%

Shares of Supernus Pharmaceuticals stock opened at $46.04 on Monday. The firm has a market capitalization of $2.58 billion, a P/E ratio of 40.03 and a beta of 0.79. The company has a 50 day moving average price of $40.67 and a 200 day moving average price of $35.08. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $46.78.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Cantor Fitzgerald boosted their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Piper Sandler boosted their price objective on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research report on Friday, August 29th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 17th. Finally, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $43.00.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.